FY2024 Earnings Estimate for KZR Issued By William Blair

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Research analysts at William Blair increased their FY2024 earnings estimates for Kezar Life Sciences in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($2.06) per share for the year, up from their prior estimate of ($12.50). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($6.47) per share. William Blair also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($2.81) EPS, Q1 2025 earnings at ($2.73) EPS, Q2 2025 earnings at ($2.75) EPS, Q3 2025 earnings at ($2.78) EPS, Q4 2025 earnings at ($2.80) EPS, FY2025 earnings at ($11.06) EPS, FY2026 earnings at ($11.86) EPS and FY2027 earnings at ($12.84) EPS.

A number of other brokerages also recently commented on KZR. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, October 14th. Wells Fargo & Company lowered their price target on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th.

Kezar Life Sciences Price Performance

Shares of NASDAQ KZR opened at $7.39 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 9.58. The company has a market cap of $53.92 million, a price-to-earnings ratio of -0.56 and a beta of 0.22. The stock’s 50-day moving average is $7.24 and its two-hundred day moving average is $6.81. Kezar Life Sciences has a 1-year low of $5.20 and a 1-year high of $11.35.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.25.

Institutional Trading of Kezar Life Sciences

A number of institutional investors have recently bought and sold shares of the business. Stonepine Capital Management LLC acquired a new stake in Kezar Life Sciences during the second quarter worth approximately $630,000. BNP Paribas Financial Markets raised its stake in Kezar Life Sciences by 35.4% during the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after acquiring an additional 71,543 shares in the last quarter. Vanguard Group Inc. lifted its position in Kezar Life Sciences by 1.0% in the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock valued at $2,790,000 after acquiring an additional 30,740 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Kezar Life Sciences by 42.5% in the first quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock valued at $1,613,000 after acquiring an additional 534,203 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Kezar Life Sciences during the second quarter worth about $63,000. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.